PARIS, Jan. 8, 2015 /PRNewswire/ -- Pharnext SAS today announced the publication of preclinical results in Nature’s Scientific Reports for its lead pleodrug, PXT-864, in Alzheimer’s disease. These data further validate its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases.
In the publication titled, “Combining two repurposed drugs as a promising approach for Alzheimer’s disease therapy” by Ilya Chumakov, et al., data show that in two different rodent models, PXT-864, a combination of baclofen and acamprosate, demonstrated not simply additive but synergistic effect. Multiple induced markers of Alzheimer’s disease models were improved and / or normalized. Indeed, PXT-864 had synergistic and consistent effects on the following:
- Significant alleviation of induced cognitive deficits in the acquisition of long and short-term memory, novel objects recognition or learning and spatial working memory
- Protection of neurons from oxidative stress and death
- Preservation of the blood brain barrier that is also damaged in patients with Alzheimer’s disease
- Normalization in levels of pro-inflammatory factors associated with neuroinflammation
- Normalization of neuronal endogenous toxic factors levels and preservation of synaptic loss
Consistently with in vivo data, researchers also noted for PXT-864 a synergistic neuronal and vascular cellular protection in two in vitro models.
The paper can be found here: http://www.nature.com/srep/2015/150108/srep07608/full/srep07608.html
Quotes
Catherine Scart-Gres, M.D., chief medical officer of Pharnext, said, “The preclinical results obtained with PXT-864 open the possibility for a promising therapeutic approach for Alzheimer’s disease. Patients suffering from Alzheimer’s disease are marked by rapid and progressive deterioration of cognitive function leading to a loss of independence. Current treatment options for these patients are only moderately symptomatic and there is a great unmet need. The preliminary data with PXT-864 are promising results for our future work. A phase 2a is currently ongoing with first results expected in 2015.”
Ilya Chumakov, Ph.D., D.Sc., co-founder of Pharnext and scientific advisory board chairman, said, “Treatment of Alzheimer’s disease was a natural direction for our pleotherapy approach because there are so many signaling pathways associated with the disease. We designed PXT-864 using our network pharmacology technology to interfere with some of those key pathways. We look forward to continuing the development of PXT-864 further in upcoming clinical trials.”
Daniel Cohen, M.D., Ph.D., chairman, chief executive officer and co-founder of Pharnext, said, “The positive data for PXT-864 published today validate our network pharmacology approach and pleotherapy platform of synergic repositioned drug combinations. We recently published positive clinical and preclinical data for our other lead pleodrug PXT-3003 in Charcot-Marie-Tooth disease Type 1A (CMT 1A). Altogether, these results comfort us in potential clinical efficacy for PXT-864 in Alzheimer’s disease. We believe there is room for development of pleodrugs in many disease conditions.”
About Alzheimer’s disease
Alzheimer’s disease is an irreversible, progressive neurodegenerative dementia. It is characterized by neuronal death in cerebral structures implicated in memory leading to cognitive deficits such as thinking, memory, personality and behavior disorders. The disease typically develops and gets worse gradually over the course of several years and ultimately leads to death. It affects around 25 million people worldwide. Unfortunately, three out of four patients are diagnosed once the disease is at a severe stage. Alzheimer’s disease has no cure and current existing therapies provide only short and modest symptomatic relief at best.
About Pharnext
Pharnext is an advanced clinical stage biopharmaceutical company developing new therapeutics that simultaneously target multiple key disease pathways for severe orphan and common neurological diseases. The proprietary research and development platform of Pharnext is based on network pharmacology. It allows the development of synergic combinations of repositioned drugs: pleodrugs. The company’s two lead pleodrugs are PXT-3003 for the treatment of Charcot Marie Tooth type 1A (Phase 2 clinical trial completed) and PXT-864 for Alzheimer’s disease (Phase 2 clinical trial ongoing) and other neurologic indications (Parkinson’s disease, amyotrophic lateral sclerosis).
For further information, visit www.pharnext.com
Pharnext Contact
Catherine Scart-Gres, M.D.
Chief Medical Officer
medical@pharnext.com
Media Contacts
Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners
T: 212-845-4251
T: 212-845-4272
tony.russo@russopartnersllc.com
matt.middleman@russopartnersllc.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharnexts-pleotherapy-shows-synergistic-effects-with-pxt-864-in-alzheimers-disease-through-preclinical-data-published-in-natures-scientific-reports-300017187.html
SOURCE Pharnext SAS
Help employers find you! Check out all the jobs and post your resume.
